Quality performance of newborn screening systems: Strategies for improvement

Journal of Inherited Metabolic Disease

Volumn 30, Issue 4, 2007, Pages 576-584

  Webster, Dian ^a  

^a National Testing Centre   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL LABORATORY; CLINICAL PROTOCOL; CONFERENCE PAPER; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; FAMILY COUNSELING; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; INBORN ERROR OF METABOLISM; LABORATORY DIAGNOSIS; MEDICAL EDUCATION; NEWBORN SCREENING; PHENYLKETONURIA; PRACTICE GUIDELINE; PUBLIC HEALTH; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

CHEMISTRY, CLINICAL; HUMANS; INFANT, NEWBORN; LABORATORIES; LABORATORY TECHNIQUES AND PROCEDURES; NEONATAL SCREENING; PUBLIC HEALTH; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY;

EID: 34548485560     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-007-0639-2     Document Type: Conference Paper

References (89)

1. AAP (2006) Update of Newborn Screening and Therapy for Congenital Hypothyroidism. American Academy of Pediatrics Susan R Rose MD and the Section on Endocrinology and Committee on Genetics American Thyroid Association Rosalind S Brown MD and the Public Health Committee Lawson Wilkins Pediatric Endocrine Society. Pediatrics 117: 2290-2303.
2. ACMG (2006a) Newborn Screening ACT sheets and confirmatory algorithms. Bethesda MD: American College of Medical Genetics. www.acmg.net.
3. ACMG (2006b) Newborn screening: Toward a uniform panel and system. Genet Med 8: 1s-252s.
4. Adam BW, Alexander JR, Smith SJ, et al (2000) Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix. Clin Chem 46: 26-28.
5. Angelini C, Federico A, Reichmann H, Lombes A, Chinnery P, Turnbull D (2006) Task force handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol 13: 923-929.
6. Bhattacharya K, Khalili V, Wiley V, Carpenter K, Wilcken B (2006) Newborn screening may fail to identify intermediate forms of maple syrup urine disease. J Inherit Metab Dis 29: 586.
7. Bollbach R, Becker M, Rotthauwe H (1985) Serum immunoreactive trypsin and pancreatic lipase in cystic fibrosis. EurJ Pediatr 144: 167-170.
8. Borrajo G, Pistaccio L, Gomez F, Di Carlo C, Castillo P, Dietz M (2006) Definition of a 17OH-progesterone birth weight adjusted cut-off value using the autodelfia method version B015. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract WS23.
9. Briard ML (2003) Neonatal screening: Definitions and criteria. [In French]. Arch Pediatr 10: 19s-21s.
10. Brosco J, Seider M, Dunn A (2006) Universal newborn screening and adverse medical outcomes: A historical note. Ment Retard Dev Disabil Res Rev 12: 262-269.
11. CDC (2007) Quality Assurance and Proficiency Testing for Newborn Screening. Bethesda, MD Centers for Disease Control. www.cdc.gov.
12. Chiang SH, Wu KF, Liu TT, Wu SJ, Hsiao KJ (2003) Quality assurance program for neonatal screening of glucose-6-phosphate dehydrogenase deficiency. Southeast Asian J Trop Med Public Health 34: 130-134.
13. CLSI (2006) Newborn Screening Followup; Approved Guideline. Clinical and Laboratory Standards Institute. www.nccls.org.
14. Como A, Accurso F, White T, et al (2007) Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation Workshop report. Pediatrics 119: E495-518.
15. Copeland S, Berberich S, Valbrecht M, Piper K (2006) Minimising risk to newborns. A system to minimise the interval from specimen collection to test result in newborn screening; 24/7 testing and delivery by courier. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P105.
16. Dhondt JL, Paux E, Farriaux J (1996) Need for a standardized procedure in the preparation of phenylalanine calibrators. Early Hum Dev 45: 277-285.
17. Dhondt JL, Loeber G, Elvers LH, Paux E (1998) Preparation of the first European working standard for phenylalanine determination in dried blood spots. J Med Screen 5: 63-67.
18. Dionisi-Vici C, Deodato F, Roschinger W, Rhead W, Wilcken B (2006) 'Classical' organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: Long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. [Report]. J Inherit Metab Dis 29: 383-389.
19. Elvers LH, Loeber JG (1996) The need for standardized bloodspot TSH-calibrators in congenital hypothyroidism screening. Early Hum Dev 45: 179-190.
20. Elvers LH, Loeber G, Dhondt JL, et al (2006) First ISNS reference preparation for neonatal screening for thyrotropin, phenylalanine and 17-alpha-hydroxyprogesterone in dried blood spots. 16th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P111.
21. Elvers LH, Loeber JG, Dhondt JL, et al (2005) First ISNS reference preparation for neonatal screening for thyrotropin, phenylalanine and 17α-hydroxyprogesterone in blood spots RIVM rapport 230011004. Rijksinstituut voor Volksgezondheid en Milieu, RIVM.
22. ESPE (1999) Revised guidelines for neonatal screening programmes for primary congenital hypothyroidism. Working Group on Neonatal Screening of the European Society for Paediatric Endocrinology. Horm Res 52: 49-52.
23. Fitness J, Dixit N, Webster D, et al (1999) Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 84: 960-966.
24. Forsberg SA (1997) Infant metabolic screening: A total quality management approach. J Obst Gynecol Neonatal Nurs 26: 257-261.
25. Fukushi M, Honma K, Yoshinaga M, et al (2006) An international training and support programme for neonatal screening in developing countries. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract SY12.
26. Green J, Hewison J, Bekker M, Bryant L, Cuckle H (2004) Psychosocial aspects of genetic screening of pregnant women and newborns: A systematic review. Health Technol Assess 8: 57-68.
27. Gruters A, Delange F, Giovannelli G, et al (1994) Guidelines for neonatal screening programs for congenital hypothyroidism. European Society for Pediatric Endocrinology Working Group on Congenital Hypothyroidism. Horm Res 41, 1-2.
28. Heeley ME, Travert G, Ferre C, Lemonnier F (1991) The international quality assurance program (IRTIQAS) for the assay of immunoreactive trypsin in dried blood spots. Pediatr Pulmonol Supplement 7: 72-75.
29. HGSA (2000) HGSA Policy on the Retention Storage and Use of Sample cards from Newborn Screening Programs. Alexandria, VIC: Human Genetics Society of Australasia. www.hgsa.com.au.
30. HGSA (2004) Policy Statement: Newborn Screening. Alexandria, VIC: Human Genetics Society of Australasia. www.hgsa.com.au.
31. Hoff T, Hoyt A (2006) Practices and perceptions of long-term follow-up among state newborn screening programs. Pediatrics 117, 1922-1929.
32. Hoff T, Hoyt A, Therrell B, Ayoob M (2006) Exploring barriers to long-term follow-up in newborn screening programs. Genet Med 8: 563-570.
33. Holzman C, Slazyk W, Codero J, Hannon H (1986) Descriptive epidemiology of missed cases of PKU and congenital hypothyroidism. Pediatrics 78 (4): 553-558.
34. Honma K, Yoshinaga M, Ota N, et al (2006) Improving the positive predictive value in newborn screening for congenital adrenal hyperplasia. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P30.
35. IAEA (2006) Screening of Newborns for Congenital Hypothyroidism. Guidance for Developing Programmes. Vienna: International Atomic Energy Agency.
36. ISNS (2005) Lexicon of Terms to be Used in Newborn Screening. Wentworthville, NSW International Society for Neonatal Screening. www.isns-neoscreening.org/pdf/Lexicon8.pdf.
37. ISNS (2007) Website. www.isns-neoscreening.org.
38. Jones JH, Mackenzie J, Croft GA, Beaton S, Young D, Donaldson MD (2006) Improvement in screening performance and diagnosis of congenital hypothyroidism in Scotland 1979-2003. Arch Dis Child 91, 680-685.
39. Kaye CI, Accurso F, La Franchi S, et al (2006) Introduction to the newborn screening fact sheets. Pediatrics 118: 1304-1312.
40. Kempers M, van der Sluijs Veer E, Nijhuis-van der Sanden R, et al (2007) Neonatal screening for congenital hypothyroidism in the netherlands: cognitive and motor outcome at 10 years of age. J Clin Endocrinol Metab 92: 919-924.
41. Li L, Zhou Y, Bell CJ, Earley MC, Hannon WH, Mei JV (2006) Development and characterization of dried blood spot materials for the measurement of immunoreactive trypsinogen. J Med Screen 13, 79-84.
42. Lindner M, Ho S, Fang-Hoffman J, Hoffmann G, Kolker S (2006) Neonatal screening for glutaric aciduria type I: Strategies to proceed. J Inherit Metab Dis 29, 378-382.
43. Loeber G, Webster D, Aznarez A (1999) Quality evaluation of newborn screening programs. Acta Paediatr Suppl 88: 3-6.
44. MacKenzie F (2007) United Kingdom External Quality Assessment Service. Neonatal Screening. http://www.ukneqas.org.uk/Directory/CC/neonatal.htm.
45. Minutti CZ, Lacey JM, Magera MJ, et al (2004) Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia.[see comment]. J Clin Endocrinol Metab 89: 3687-3693.
46. Naruse H, Tsuji A, Suzuki E, et al (2003) Quality control system for mass screening in Japan. Southeast Asian J Trop Med Public Health 34: 30-35.
47. NCCLS (2003) Blood collection on filter paper for Newborn Screening Programs; Approved Standard. Clinical and Laboratory Standards Institute. www.nccls.org.
48. Oglesbee D, Lacey J, Spolar C, et al (2006) Newborn screening for MSUD: increased specificity by addition of 2nd-tier assay for allo-isoleucine by LC-MS/MS 16th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P88.
49. Oglesbee D, He M, Majumder N, et al (2007) Development of a newborn screening followup algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. Genet Med 9: 108-116.
50. Olgemoller B, Roscher A, Adelbert A, Liebl B, Fingerhut R (2003) Screening for congenital adrenal hyperplasia: Adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab 88: 5790-5794.
51. Oltarzewski M, Jablonska E, Nowacka M, Radomyska B (2006) Comparison of tandem mass spectrometry (MS/MS) with colorimetric test in newborn screening for phenylketonuria discrimination power and cut-off values. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P33.
52. Pass K, Levy H, eds (1995) Early Hospital Discharge: Impact on Newborn Screening. Atlanta GA: Council of Regional Networks for Genetic Services.
53. Patch C (2006) Newborn screening policy in the United Kingdom, the United States: Two different communities of practice. [Review] [22 refs]. MCN, Am J Maternal Child Nurs 31: 164-168.
54. Paterson R (1999) Auckland Healthcare Services Limited Health and Disability Commisioner's Report on Opinion Case 99hdc09011.
55. Pollitt R (2006a) Sensitivity, specificity and the 'ethnic question': controversies surrounding CF screening in the UK 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract WS16.
56. Pollitt RJ (2006b) Newborn screening policies in the UK: Progress and problems. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract SY19.
57. Pollitt R (2006c) International perspectives on newborn screening. J Inherit Metabc Dis 29: 390-396.
58. Pollitt R, Matthews A (2006) Population centile-centile plots for monitoring assay performance. 6th ISNS International Meeting, Awaji/ Tokoshima, Japan, Abstract P110.
59. Pollitt RJ, Dalton A, Evans S, Hughes HN, Curtis D (1997) Neonatal screening for cystic fibrosis in the Trent region (UK): Two-stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step. J Med Screen 4: 23-28.
60. Raimann E, Valiente A, Soto V, Cabello F, Cornejo V (2006) Succinylacetone assay in dried blood on filter paper. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P60.
61. Rinaldo P, Safari S, Tortorelli S, Matern D (2006a) Newborn screening of metabolic disorders by tandem mass spectrometry: The impact of performance on the cost-benefit equation. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract PL5.
62. Rinaldo P, Tortorelli S, Matern D (2006b) Improved specificity of newborn screening for congenital adrenal hyperplasia by steroid profiling using tandem mass spectrometry. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract WS17.
63. Roussey M, Le Bihannic A, Audrezet M, et al (2006) Neonatal Screening (NNS) of CF: Diagnostic problems with CFTR mild mutations. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P74.
64. Rovet J, Daneman D (2003) Congenital hypothyroidism: A review of current diagnostic and treatment practices in relation to neuropsychologic outcome. [Review] [96 refs]. Paediatr Drugs 5: 141-149.
65. Schymik I, Liebig M, Mueller M, et al (2006) Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. J Pediatr 149: 128-130.
66. Shepherd AJ, Glenesk A, Niven CA, Mackenzie J (2006) A Scottish study of heel-prick blood sampling in newborn babies. Midwifery 22: 158-168.
67. Sherwin J, She J, Bhandal A (2006) California newborn screening for congenital adrenal hyperplasia using two tier test system with birthweight adjusted cutoffs for improved precision. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract SY3.
68. Simon E, Flaschker N, Schadewaldt P, Langenbeck U, Wendel U (2006) Variant maple syrup urine disease (MSUD) - The entire spectrum. J Inherit Metab Dis 29: 716-724.
69. Suolinna EM, Torresani TE, Westgard JO (2003) Designing quality control for neonatal screening assays. Southeast Asian J Trop Med Public Health 34: 103-106.
70. Sweetman L, Forni S, Alvarado L, Roe D, Fu X, Roe C (2006) Second tier testing for the differential diagnosis of short-chain acyl-CoA dehydrogenase deficiency, isobutyryl-CoA dehydrogenase deficiency, isovaleric acidemia and 2-methylbutyryl-CoA dehydrogenase deficiency. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P7.
71. Therrell B (2007) Program Evaluation and Assessment Scheme (PEAS). http://genes-r-us.uthscsa.edu/PEAS.doc.
72. Therrell B, Hannon H (2006) National Evaluation of newborn screening system components. Ment Retard Dev Disabil Res Rev 12: 236-245.
73. Therrell B, Panny S, Davidson A, et al (1992) US Newborn Screening System Guidelines: Statement of the Council of Regional Networks for Genetic Services. Screening 1: 135-149.
74. Therrell B, Hannon H, Pass K, et al (1996) Guidelines for the Retention Storage and Use of Residual Dried Blood Spot Samples after Newborn Screening Analysis: Statement of the Council of Regional Networks for Genetic Services. Biochemistry Mol Med 57, 116-124.
75. Tillotson SL, Fuggle PW, Smith I, Ades AE, Grant DB (1994) Relation between biochemical severity and intelligence in early treated congenital hypothyroidism: A threshold effect. Br Med J 309: 440-445.
76. Torresani T (2003) Quality control requirements in neonatal screening. Eur J Pediatr 162: S54-56.
77. Tuuminen T, Kapyaho K, Rakkolainen A, Weber T (1994) Analytical quality control in neonatal screening. Clin Biochem 27: 429-434.
78. UK (2005) Newborn blood spot screening in the UK Policies and Standards. UK Newborn Screening Programme Centre. London: Department of Health. www.newbornscreening-bloodspot.org.uk.
79. Wald N, Leck I (2000) Antenatal and newborn screening. Oxford: Oxford University Press.
80. Wang S, Pizzolato S, Demshar H (1997) Receiver operatoing characteristic plots to evaluate Guthrie Wallac and Isolab phenylalanine kit performance for newborn phenylketonuria screening. Clin Chem 43: 1838-1842.
81. Wang W, Chen X, Zang J, He Y, Zhang P, Shen F (2003) Development of a newborn screening laboratory quality assurance system in Shandong China. Southeast Asian J Trop Med Public Health 34: 36-38.
82. Watanabe N, Suzuki E, Ikegami M, et al (2006) Quality control of the materials and reagents for neonatal screening in Japan. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P114.
83. Webster D, Dhondt JL, Hannon WH, Loeber G, Torresani T (1999) Quality assurance and standardization: Summary of the satellite meeting Turku Finland, 11-12 June 1999. Acta Paediatr Suppl 88: 7-12.
84. Wilcken B (2006a) Mini-Symposium: Newborn screening for inborn errors of metabolism - Clinical effectiveness. J Inherit Metab Dis 29, 366-369.
85. Wilcken B (2006b) Newborn screening by tandem mass spectrometry assessing the benefits. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract SY22.
86. Wilcken B, Wiley V, Sherry G, Bayliss U (1995) Neonatal screening for cystic fibrosis: A comparison of two strategies for case detection in 1.2 million babies. J Pediatr 127: 965-970.
87. Wiley V, Carpenter K, Wilcken B (2006a) Detection of inborn errors of metabolism in newborns using tandem mass spectrometry - Lessons learned. 6th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P141.
88. Wiley V, Tan E, Wilcken B (2006b) Non-ketotic hyperglycinaemia is usually not detectable by tandem mass spectrometry newborn screening. 16th ISNS International Meeting, Awaji/Tokoshima, Japan, Abstract P90.
89. Wilson J, Junger G (1968) Principles and Practice of Screening for Disease. Geneva: World Health Organization.